Sorriso Pharmaceuticals

Dr. Vipul Jairath recently presented the SOR102 Phase 1b ulcerative colitis data during the “Hot Topics” plenary session at the 2025 ECCO conference in Berlin, Germany. The SOR102 Phase 1b study was selected amongst the top 10 oral abstracts of ECCO 2025, highlighting it as one of the most important scientific insights presented at the conference. Thank you Max Gelman of Endpoints News for continuing to follow the SOR102 story and?for this article covering the clinical data from our Phase 1b study of SOR102. You can read the full article here: https://lnkd.in/dvRYCy2Q and Sorriso's recent press release here: https://lnkd.in/graATNv4 #UlcerativeColitis #IBD #ClinicalTrials #AutoimmuneDisease #OralBiologics

We are proud to announce positive Phase 1b clinical trial results for SOR102, our first-in-class oral biologic for ulcerative colitis. This study marks the first successful demonstration of an orally dosed antibody delivering clinical efficacy, showing statistically significant improvements across multiple clinical endpoints, with a favorable safety and tolerability profile. As our CEO, Ciara Kennedy, shared: “SOR102 represents a game changer in the treatment of inflammatory bowel disease. By combining efficacy and convenience in an oral therapy, we aim to transform the standard of care and improve the lives of patients living with ulcerative colitis.” We are excited to advance SOR102 into Phase 2 development in 2025 and continue building on this milestone. Read the press release here: https://lnkd.in/d_8C-TgK Also see this exclusive article by Max Gelman in Endpoints News: https://lnkd.in/dHwgxs9Y #UlcerativeColitis #IBD #ClinicalTrials #AutoimmuneDisease #DrugDevelopment #Biologics #OralTherapies #CombinationTherapy

We are thrilled to announce that Sorriso has successfully completed enrollment in our Phase 1b clinical trial of patients with ulcerative colitis, marking a significant step forward in the development of SOR102. https://lnkd.in/gSKXMCnJ

The Sorriso team had a blast joining the Crohn's & Colitis Foundation at Take Steps in San Diego this past weekend. Take Steps is the Foundation's largest nationwide fundraising campaign, to raise awareness and funds to accelerate the progress of breakthrough inflammatory bowel disease (IBD) research and to support critical patient programs. If you would like to donate to our team fundraising you can do so at https://lnkd.in/e7v3xVvV

Sorriso is excited to announce we have dosed the first patients in our Phase 1b clinical trial for patients with ulcerative colitis. https://lnkd.in/gjbPhTbc